Ribo Life Science 06938HK Successfully Lists on the Main Board of the Hong Kong Stock Exchange
HONG KONG, Jan. 9, 2026 PRNewswire -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry. In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong dollars, HKPO was over 100x oversubscribed, International Placing was 16.7x oversubscribed, reflecting strong global investor confidence in the value of the siRNA sector and the Company's capabilities. 🔗 Leggi su Iltempo.it
Leggi anche: Eni, celebra 30 anni di quotazione al New York Stock Exchange
Leggi anche: ISX Financial EU Plc exits National Stock Exchange of Australia (NSX Ltd)
Aggiornamenti e dibattiti
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange.
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange - HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong ... adnkronos.com
Ribo Life Science: Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection - and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has ... finanznachrichten.de
➜